Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
Stanley Cohan, Ralph H. B. Benedict, Bruce Cree, et al.
CNS Drugs (2022) Vol. 36, Iss. 7, pp. 703-719
Open Access | Times Cited: 24

Showing 24 citing articles:

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
LPA 2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction
Jianqiu Pei, Lin Cai, Fang Wang, et al.
Circulation Research (2022) Vol. 131, Iss. 5, pp. 388-403
Open Access | Times Cited: 38
Central nervous system demyelinating diseases: glial cells at the hub of pathology
Vinicius Gabriel Coutinho Costa, Sheila Espírito-Santo Araújo, Soniza Vieira Alves‐Leon, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Causal relationship between multiple sclerosis and cortical structure: a Mendelian randomization study
Dongren Sun, Rui Wang, Qin Du, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
Antonios Bayas, Monika Christ, Simon Faissner, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 17
Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications
Zhen-Xi Niu, Jing Hu, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116446-116446
Closed Access | Times Cited: 7
Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury
Devaraj Basavarajappa, Vivek Gupta, Nitin Chitranshi, et al.
Molecular Neurobiology (2023) Vol. 60, Iss. 12, pp. 7222-7237
Open Access | Times Cited: 11
Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
Ariane Mwema, Giulio G. Muccioli, Anne des Rieux
Journal of Controlled Release (2023) Vol. 364, pp. 435-457
Closed Access | Times Cited: 9
First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
Ludger Starke, Jason M. Millward, Christian Prinz, et al.
Theranostics (2023) Vol. 13, Iss. 4, pp. 1217-1234
Open Access | Times Cited: 8
S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights
Omid Jamshidi Kandjani, Shadi Yaqoubi, Samad Shams Vahdati, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115182-115182
Closed Access | Times Cited: 7
Improved synthesis, molecular modeling and anti-inflammatory activity of new fluorinated dihydrofurano-naphthoquinone compounds
Ha Thanh Nguyen, Hai Pham‐The, Nguyen Tuan Anh, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 104, pp. 129714-129714
Closed Access | Times Cited: 2
Unveiling enigmatic essence of Sphingolipids: A promising avenue for glaucoma treatment
Igor Iezhitsa, Renu Agarwal, Puneet Agarwal
Vision Research (2024) Vol. 221, pp. 108434-108434
Closed Access | Times Cited: 2
S1PR1 signaling attenuates apoptosis of retinal ganglion cells via modulation of cJun /Bim cascade and Bad phosphorylation in a mouse model of glaucoma
Devaraj Basavarajappa, Vivek Gupta, Roshana Vander Wall, et al.
The FASEB Journal (2022) Vol. 37, Iss. 1
Open Access | Times Cited: 10
Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?
David Martín‐Hernández, Marina Muñoz‐López, Hiram Tendilla‐Beltrán, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12634-12634
Open Access | Times Cited: 5
The role of sphingosine-1-phosphate in the development and progression of Parkinson’s disease
Wang Wang, Yang Zhao, Guoxue Zhu
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 5
LPA2 Alleviates Septic Acute Lung Injury via Protective Endothelial Barrier Function Through Activation of PLC-PKC-FAK
Ruifeng Bai, Jianqiu Pei, Shengqiang Pei, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 5095-5109
Open Access | Times Cited: 3
Carboxylic Acid-Containing Indanyl Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases
Ram W. Sabnis, Anika R. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 8, pp. 1033-1034
Open Access | Times Cited: 2
Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases
Ram W. Sabnis, Anika R. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 750-751
Open Access
Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study
Eman Saleh Omar, Hayat M. Suliman, Bashier Osman, et al.
The Egyptian Journal of Neurology Psychiatry and Neurosurgery (2024) Vol. 60, Iss. 1
Open Access
Impact of Siponimod on Clinical and Radiological Parameters of Secondary Progressive Multiple Sclerosis: A Real-World Prospective Study
Konstantina Stavrogianni, Dimitrios K. Kitsos, Vasileios Giannopapas, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 6, pp. 591-591
Open Access
PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
O. V. Somilo, O. I. Kalbus, S. O. Makarov, et al.
World of Medicine and Biology (2023) Vol. 19, Iss. 84, pp. 147-147
Closed Access | Times Cited: 1
Quantitative Analysis of S1PR1 Expression in the Postmortem Multiple Sclerosis Central Nervous System
Hao Jiang, Charles Zhou, Lin Qiu, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 22, pp. 4039-4050
Closed Access | Times Cited: 1
Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up
Rebecca Ludwig, Bimala Malla, Maria Höhrhan, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 261-261
Open Access | Times Cited: 1
Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
Marc Bigaud, Pamela Ramseier, Sarah Tisserand, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 4, pp. 1187-1203
Open Access
Page 1

Scroll to top